Basilea's Toctino (alitretinoin) receives marketing authorization in France
Following the recommendation for regulatory approval under the European decentralized procedure, Toctino® has received national regulatory approval in France. Basilea will submit a pricing and reimbursement dossier to the French authorities based on the approval.
Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema are also under regulatory review in Canada and in Switzerland.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.